litlas
Log inCreate account

Timothy P. Hughes

Active 1979–2025

155
Papers
46,786
Citations
94
h-index
144
i10-index

Citations

Citations per year for Timothy P. Hughes1979: 14 citations1988: 2 citations1989: 2 citations1990: 8 citations1991: 10 citations1992: 8 citations1993: 9 citations1994: 13 citations1995: 14 citations1996: 12 citations1997: 13 citations1998: 16 citations1999: 18 citations2000: 20 citations2001: 22 citations2002: 30 citations2003: 100 citations2004: 148 citations2005: 168 citations2006: 226 citations2007: 276 citations2008: 308 citations2009: 418 citations2010: 444 citations2011: 414 citations2012: 420 citations2013: 391 citations2014: 403 citations2015: 414 citations2016: 391 citations2017: 295 citations2018: 284 citations2019: 1,012 citations2020: 1,154 citations2021: 1,022 citations2022: 802 citations2023: 479 citations2024: 1,017 citations2025: 401 citations2026: 10 citations1980–1987: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,689 citing papers, 27.2% of this breakdownGermany: 709 citing papers, 7.2% of this breakdownUnited Kingdom: 706 citing papers, 7.2% of this breakdownItaly: 625 citing papers, 6.3% of this breakdownChina: 606 citing papers, 6.1% of this breakdownFrance: 474 citing papers, 4.8% of this breakdownAustralia: 361 citing papers, 3.7% of this breakdownCanada: 302 citing papers, 3.1% of this breakdownSwitzerland: 290 citing papers, 2.9% of this breakdownNetherlands: 273 citing papers, 2.8% of this breakdownJapan: 271 citing papers, 2.7% of this breakdownSpain: 243 citing papers, 2.5% of this breakdown
0%27.2%Other 23.5%

Institutions

Fields

  • Medicine68.9%
  • Biochemistry, Genetics and Molecular Biology18.6%
  • Immunology and Microbiology4.1%
  • Agricultural and Biological Sciences4%
  • Computer Science1%
  • Mathematics0.7%
  • Other2.7%

Topics

  • Chronic Myeloid Leukemia Treatments14.3%
  • Chronic Lymphocytic Leukemia Research7.3%
  • Eosinophilic Disorders and Syndromes5.5%
  • Acute Lymphoblastic Leukemia research5.4%
  • Acute Myeloid Leukemia Research5.1%
  • Cancer Genomics and Diagnostics1.9%
  • Other60.5%

Coauthors

All papers

Open in search
  1. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Authors: Andreas Hochhaus, Michele Baccarani, Richard T. Silver, CA Schiffer, Jane F. Apperley, Francisco Cervantes, R E Clark, J. E. Cortes, Michael W. Deininger, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, J. Janssen, Hagop M. Kantarjian, D. W. Kim, Richard A. Larson, J. H. Lipton, F.-X. Mahon, Jiří Mayer, Franck E. Nicolini, D Niederwieser, Fabrizio Pane, Jerald P. Radich, Delphine Réa, Johan Richter, G Rosti, Philipe Rousselot, Giuseppe Saglio, Susanne Saußele, Simona Soverini, J. L. Steegmann, Anna Turkina, Andrey Zaritskey, R. Hehlmann - Leukemia 2020 cited by 1,510

  2. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

    Authors: Delphine Réa, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong‐Wook Kim, Jane F. Apperley, André Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saußele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Koji Sasaki, Lynette Chee, Valentín García‐Gutiérrez, Jörge E. Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus - Blood 2021 cited by 336

  3. The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

    Authors: Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke, Sandra W. Cowan‐Jacob, Alice Loo, Pascal Furet, Andreas L. Marzinzik, Xavier Pellé, Jerry Donovan, Wenjing Zhu, Silvia Buonamici, Amr Hassan, Franco Lombardo, Varsha Iyer, Michael R. Palmer, Giuliano Berellini, Stephanie Dodd, Sanjeev Thohan, Hans Bitter, Susan Branford, David M. Ross, Timothy P. Hughes, Lilli Petruzzelli, K. Gary J. Vanasse, Markus Warmuth, Francesco Hofmann, Nicholas Keen, William R. Sellers - Nature 2017 cited by 614

  4. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Authors: Andreas Hochhaus, Richard A. Larson, François Guilhot, Jerald P. Radich, Susan Branford, Timothy P. Hughes, Michele Baccarani, Michael W. Deininger, Francisco Cervantes, Satoko Fujihara, Christine-Elke Ortmann, Hans D. Menssen, Hagop Kantarjian, Stephen G. O’Brien, Brian Druker - New England Journal of Medicine 2017 cited by 1,259

  5. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

    Authors: Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes, Hironobu Minami, Delphine Réa, Daniel J. DeAngelo, Massimo Breccia, Yeow-Tee Goh, Moshe Talpaz, Andreas Hochhaus, Philipp le Coutre, Oliver G. Ottmann, Michael C. Heinrich, Juan Luis Steegmann, Michael W. Deininger, Jeroen J. W. M. Janssen, François-Xavier Mahon, Yosuke Minami, David T Yeung, David M. Ross, Martin S. Tallman, Jae H. Park, Brian Druker, David Hynds, Yuyan Duan, Christophe Meille, Florence Hourcade‐Potelleret, K. Gary J. Vanasse, Fabian Lang, Dong‐Wook Kim - New England Journal of Medicine 2019 cited by 467

  6. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Authors: Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Siu‐Fun Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M. Goldman, Neil P. Shah, Hagop M. Kantarjian - New England Journal of Medicine 2013 cited by 1,124

  7. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    Authors: Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian - Blood 2018 cited by 583

  8. Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

    Authors: Kathryn G. Roberts, Yongjin Li, Debbie Payne-Turner, Richard C. Harvey, Yung‐Li Yang, Deqing Pei, Kelly McCastlain, Li Ding, Charles Lu, Guangchun Song, Jing Ma, Jared Becksfort, Michael Rusch, Shann-Ching Chen, John Easton, Jinjun Cheng, Kristy Boggs, Natalia Santiago-Morales, Ilaria Iacobucci, Robert S. Fulton, Ji Wen, Marcus Valentine, Cheng Cheng, Steven W. Paugh, Meenakshi Devidas, I‐Ming Chen, Shalini C. Reshmi, Amy Smith, Erin Hedlund, Pankaj Gupta, Panduka Nagahawatte, Gang Wu, Xiang Chen, Donald Yergeau, Bhavin Vadodaria, Heather L. Mulder, Naomi Winick, Eric Larsen, William L. Carroll, Nyla A. Heerema, Andrew J. Carroll, Guy H. Grayson, Sarah K. Tasian, Andrew S. Moore, Frank Keller, Melissa Frei‐Jones, James A. Whitlock, Elizabeth A. Raetz, Deborah L. White, Timothy P. Hughes, Jaime M. Guidry Auvil, Malcolm A. Smith, Guido Marcucci, Clara D. Bloomfield, Krzysztof Mrózek, Jessica Kohlschmidt, Wendy Stock, Steven M. Kornblau, Marina Konopleva, Elisabeth Paietta, Ching‐Hon Pui, Sima Jeha, Mary V. Relling, William E. Evans, Daniela S. Gerhard, Julie M. Gastier-Foster, Elaine R. Mardis, Richard K. Wilson, Mignon L. Loh, James R. Downing, Stephen P. Hunger, Cheryl L. Willman, Jinghui Zhang, Charles G. Mullighan - New England Journal of Medicine 2014 cited by 1,376

  9. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

    Authors: Brian Druker, François Guilhot, Stephen G. O’Brien, Insa Gathmann, Hagop M. Kantarjian, Norbert Gattermann, Michael W. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy P. Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John D. Shepherd, Giuseppe Saglio, Aloïs Gratwohl, Johan Lanng Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson - New England Journal of Medicine 2006 cited by 3,481

  10. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

    Authors: Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jörge E. Cortes, Timothy P. Hughes, Jane F. Apperley, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong‐Wook Kim, André Abdo, Laura Fogliatto, Philipp le Coutre, Koji Sasaki, Dennis Dong Hwan Kim, Susanne Saußele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, Valentín García‐Gutiérrez, S. S. Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J. Mauro - Leukemia 2023 cited by 135

  11. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

    Authors: Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson, Dong‐Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Étienne, Carla Boquimpani, Ricardo Pasqüini, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Sławomira Kyrcz‐Krzemień, Ewa Mędraś, Maria Aparecida Zanichelli, Israel Bendit, Silvia Cacciatore, Ksenia Titorenko, Paola Aimone, Giuseppe Saglio, Andreas Hochhaus - Leukemia 2021 cited by 351

  12. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    Authors: Stephen G. O’Brien, François Guilhot, Richard A. Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J. Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy P. Hughes, Klaus Lechner, Johan Lanng Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John D. Shepherd, Bengt Simonsson, Aloïs Gratwohl, John M. Goldman, Hagop M. Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E. Bolton, Renaud Capdeville, Brian Druker - New England Journal of Medicine 2003 cited by 3,565

  13. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

    Authors: Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes, Richard A. Larson, D-W Kim, Surapol Issaragrisil, Philipp D. le Coutre, Gabriel Étienne, P.E. Dorlhiac‐Llacer, Richard E. Clark, Ian W. Flinn, Hirohisa Nakamae, Breanne Donohue, Weiping Deng, Darshan Dalal, Hans D. Menssen, Hagop M. Kantarjian - Leukemia 2016 cited by 850

  14. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia

    Authors: Nadia El Khawanky, Amy Hughes, Wenbo Yu, Renier Myburgh, Tony Matschulla, Sanaz Taromi, Konrad Aumann, Jade Clarson, Janaki Manoja Vinnakota, Khalid Shoumariyeh, Cornelius Miething, Angel F. López, Michael P. Brown, Justus Duyster, Lutz Hein, Markus G. Manz, Timothy P. Hughes, Deborah L. White, Agnes S. M. Yong, Robert Zeiser - Nature Communications 2021 cited by 102

  15. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

    Authors: Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil, P. Le Coutre, Gabriel Étienne, Clarisse Lobo, Ricardo Pasqüini, Richard E. Clark, Andreas Hochhaus, Timothy P. Hughes, Neil J. Gallagher, Albert Hoenekopp, Mei Dong, Md Ariful Haque, Richard A. Larson, Hagop M. Kantarjian - New England Journal of Medicine 2010 cited by 1,679

  16. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

    Authors: Andreas Hochhaus, Jianxiang Wang, Dong‐Wook Kim, Dennis Dong Hwan Kim, Jiřı́ Mayer, Yeow‐Tee Goh, Philipp le Coutre, Naoto Takahashi, In Ho Kim, Gabriel Étienne, David Andorsky, Ghayas C. Issa, Richard A. Larson, Felice Bombaci, S. S. Kapoor, Tracey McCulloch, Kamel Malek, Lillian Yau, Sophie Ifrah, Matthias Hoch, Jörge E. Cortes, Timothy P. Hughes - New England Journal of Medicine 2024 cited by 139

  17. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Authors: Michele Baccarani, Michael Deininger, Gianantonio Rosti, Andreas Hochhaus, Simona Soverini, Jane F. Apperley, Francisco Cervantes, Richard E. Clark, Jörge E. Cortes, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, Hagop M. Kantarjian, Dong‐Wook Kim, Richard A. Larson, Jeffrey H. Lipton, François-Xavier Mahon, Giovanni Martinelli, Jiřı́ Mayer, Martin Müller, Dietger Niederwieser, Fabrizio Pane, Jerald P. Radich, Philippe Rousselot, Giuseppe Saglio, Susanne Saußele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Juan-Luis Steegmann, John M. Goldman, Rüdiger Hehlmann - Blood 2013 cited by 1,989

  18. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

    Authors: Charles G. Mullighan, Christopher B. Miller, Ina Radtke, Letha A. Phillips, James Dalton, Jing Ma, Deborah L. White, Timothy P. Hughes, Michelle M. Le Beau, Ching‐Hon Pui, Mary V. Relling, Sheila Shurtleff, James R. Downing - Nature 2008 cited by 1,081

  19. Lin28 promotes transformation and is associated with advanced human malignancies

    Authors: Srinivas R. Viswanathan, John T. Powers, William S. Einhorn, Yujin Hoshida, Tony Ng, Sara Toffanin, Maureen J. O’Sullivan, Jun Lü, Letha A. Phillips, Victoria L Lockhart, Samar P. Shah, Pradeep S. Tanwar, Craig H. Mermel, Rameen Beroukhim, Mohammad Azam, Jose M. Teixeira, Matthew Meyerson, Timothy P. Hughes, Josep M. Llovet, Jerald P. Radich, Charles G. Mullighan, Todd R. Golub, Poul H. Sorensen, George Q. Daley - Nature Genetics 2009 cited by 820

  20. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

    Authors: Michael J. Mauro, Timothy P. Hughes, Dong‐Wook Kim, Delphine Réa, Jörge E. Cortes, Andreas Hochhaus, Koji Sasaki, Massimo Breccia, Moshe Talpaz, Oliver G. Ottmann, Hironobu Minami, Yeow Tee Goh, Daniel J. DeAngelo, Michael C. Heinrich, Valle Gómez-Garcı́a de Soria, Philipp le Coutre, François‐Xavier Mahon, Jeroen J. W. M. Janssen, Michael W. Deininger, Naranie Shanmuganathan, Mark B. Geyer, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Matthias Hoch, Fabian Lang - Leukemia 2023 cited by 47

  21. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

    Authors: Jeffrey H. Lipton, Charles Chuah, Agnès Guerci‐Bresler, Gianantonio Rosti, David Simpson, Sarit Assouline, Gabriel Étienne, Franck E. Nicolini, Philipp le Coutre, Richard E Clark, Leif Stenke, David Andorsky, Vivian G. Oehler, Stephanie Lustgarten, Victor M. Rivera, Timothy Piers Clackson, Frank G. Haluska, Michele Baccarani, Jörge E. Cortes, François Guilhot, Andreas Hochhaus, Timothy P. Hughes, Hagop M. Kantarjian, Neil P. Shah, Moshe Talpaz, Michael Deininger - The Lancet Oncology 2016 cited by 259

  22. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

    Authors: David M. Ross, Susan Branford, John F. Seymour, Anthony P. Schwarer, Christopher Arthur, David T Yeung, Phuong Dang, Jarrad M. Goyne, Cassandra Slader, Robin Filshie, Anthony K. Mills, Junia V. Melo, Deborah L. White, Andrew Grigg, Timothy P. Hughes - Blood 2013 cited by 706

  23. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

    Authors: Jörge E. Cortes, Koji Sasaki, Dong‐Wook Kim, Timothy P. Hughes, Gabriel Étienne, Michael J. Mauro, Andreas Hochhaus, Fabian Lang, Michael C. Heinrich, Massimo Breccia, Michael W. Deininger, Yeow Tee Goh, Jeroen J. W. M. Janssen, Moshe Talpaz, Valle Gomez Garcia de Soria, Philipp le Coutre, Daniel J. DeAngelo, Andrea Damon, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Delphine Réa - Leukemia 2024 cited by 51

  24. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Authors: Michele Baccarani, Jörge E. Cortes, Fabrizio Pane, Dietger Niederwieser, Giuseppe Saglio, Jane F. Apperley, Francisco Cervantes, Michael W. Deininger, Aloïs Gratwohl, François Guilhot, Andreas Hochhaus, Mary M. Horowitz, Timothy P. Hughes, Hagop M. Kantarjian, Richard A. Larson, Jerald P. Radich, Bengt Simonsson, Richard T. Silver, John M. Goldman, Rüdiger Hehlmann - Journal of Clinical Oncology 2009 cited by 1,298